ASH Annual Meeting and Exposition
ASH Annual Meeting and Exposition
December 02, 2019
1 min read

Highlights in lymphoma research to look forward to at ASH 2019

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Joshua Brody

Joshua Brody, MD, director of the lymphoma immunotherapy program, Icahn School of Medicine at Mount Sinai, and HemOnc Today Next Gen Innovator, discussed some highlights to look forward to at this year’s ASH annual meeting, including novel therapeutics and how the data will impact clinical practice.

What should clinicians expect from attending ASH related to lymphoma?

ASH 2019 will be one of the more exciting meetings in recent years, revealing anticipated data in lymphoma and chronic lymphocytic leukemia (CLL), especially regarding some clinically relevant novel therapeutics like T-cell based therapies (bi-specific antibodies and CAR-T) and newer generation BTK inhibitors.

What are you most excited for related to lymphoma that’s happening at the meeting?

Remarkably high response rates for our patients who have previously been in terrible situations, such as relapsed and refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), with fairly safe, non-chemotherapy based options, such as bi-specific antibodies and CD19 antibody with lenalidomide (Revlimid, Celgene). These are exactly what our patients are looking for – therapies that attack lymphoma in a completely different way than how chemotherapy works, which can induce prolonged remissions.

What impact does ASH usually have on your practice?

For every practicing hematologist/oncologist, ASH will present data that impact everyday clinical practice, eg, novel data from the Elevate-TN trial supporting a new first line CLL FDA-approval for acalabrutinib (Calquence, AstraZeneca) showing profound benefit compared with chemotherapy (90% reduction in risk for progression) from an extremely well-tolerated oral therapy.

For hematologist/oncologists who see patients in especially difficult situations, like relapsed and refractory DLBCL and FL, the wonderfully high response rates for new bi-specifics like mosunetuzumab and REGN1979 will definitely be practice-changing and change the way we care for these patients in 2020.

Disclosures: Brody reports research funding from BMS, Celldex Therapeutics, Genentech, Kite Pharma and Merck.